# Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next

## TL;DR

This review discusses how mRNA vaccines are emerging as a promising new treatment for prostate cancer, with potential for personalized therapy.

## Contribution

The paper highlights recent advancements in mRNA vaccine development for prostate cancer and outlines future directions for improving efficacy.

## Key findings

- mRNA vaccines show promise in early clinical trials for prostate cancer, such as CV9103/4.
- Advancements in lipid nanoparticle delivery and combination with checkpoint inhibitors are improving treatment outcomes.
- Challenges like antigen selection and the tumor microenvironment remain critical for future progress.

## Abstract

Prostate cancer (PC) treatment is evolving beyond conventional therapies. This review explores mRNA-based vaccines as a promising immunotherapy. We discuss their mechanism of action, advantages in production and safety, and results from early clinical trials (e.g., CV9103/4). Key challenges like antigen selection and the immunosuppressive tumor microenvironment are addressed, alongside advancements in lipid nanoparticle delivery and combinatorial strategies with checkpoint inhibitors to enhance efficacy and usher in personalized PC treatment.